Question

Difficulty: MediumPsychiatric Emergencies and Legal/Ethical Issues

Paramedics transport a 41-year-old male accountant to the emergency department after his wife found him acutely confused and sweating profusely at home. The patient has a long-standing history of major depressive disorder that has been difficult to manage. Five days ago, his outpatient psychiatrist discontinued his fluoxetine and immediately initiated a prescription for phenelzine to target different neurotransmitter receptors. On examination, the patient is visibly shivering, highly agitated, and disoriented to time and place. Vital signs reveal a temperature of 39.5∘C39.5^\circ\text{C} (103.1∘F103.1^\circ\text{F}), blood pressure of 168/102 mm Hg168/102\text{ mm Hg}, and a heart rate of 124/min124\text{/min}. Neurological evaluation demonstrates dilated pupils, marked bilateral hyperreflexia in the lower extremities, and sustained ankle clonus. The medical team promptly discontinues all psychiatric medications and administers intravenous normal saline along with a dose of intravenous lorazepam. Thirty minutes later, the patient remains profoundly agitated, and his hyperthermia and clonus are completely unchanged. Which of the following is the most appropriate next step in management?

  1. A
    Administer bromocriptine
  2. B
    Administer dantrolene
  3. Administer cyproheptadineAnswer
  4. D
    Administer haloperidol
  5. E
    Administer flumazenil

Answer

Administer cyproheptadine
The correct next step is to administer cyproheptadine. This patient is experiencing severe Serotonin Syndrome, precipitated by the premature initiation of an MAOI (phenelzine) immediately after discontinuing fluoxetine. Fluoxetine has a uniquely long half-life and requires a 5-week washout period before starting an MAOI to prevent this life-threatening drug interaction. The classic triad of Serotonin Syndrome includes altered mental status, autonomic hyperactivity, and neuromuscular abnormalities (specifically hyperreflexia and clonus, which distinguish it from NMS). Because the patient's symptoms (hyperthermia and agitation) failed to improve with standard initial therapy consisting of offending agent discontinuation, IV fluids, and benzodiazepines, targeted serotonin antagonism with cyproheptadine is strictly indicated.

Step-by-Step Solution

1
Identify the toxidrome based on the clinical presentation and medication history.
The combination of altered mental status, autonomic instability (hyperthermia, tachycardia, diaphoresis), and neuromuscular hyperactivity (hyperreflexia, sustained ankle clonus) strongly indicates Serotonin Syndrome.
The patient was transitioned from fluoxetine directly to an MAOI (phenelzine) without the mandatory 5-week washout period, leading to a massive accumulation of synaptic serotonin.
2
Evaluate the response to initial, first-line management interventions.
The patient received appropriate initial therapy (discontinuation of serotonergic agents, IV fluids, and IV benzodiazepines) but remained profoundly symptomatic and agitated.
While mild to moderate cases often resolve with supportive care and benzodiazepines alone, severe or refractory cases require targeted pharmacologic antagonism.
3
Select the specific pharmacologic antidote for the refractory condition.
Cyproheptadine should be administered.
Cyproheptadine is a first-generation histamine antagonist with strong serotonin (5-HT1A and 5-HT2A) antagonistic properties, making it the definitive next step for Serotonin Syndrome unresponsive to initial supportive measures.

Key Concept

Management of severe Serotonin Syndrome requires discontinuation of offending agents, supportive care with IV fluids and benzodiazepines, and administration of cyproheptadine for refractory symptoms.
Rate this question